Vendor Intelligence Report: Tianjin Finder Chemical TFC

Published 12 Jun 2026. 21-page investigative report on who is behind Tianjin Finder Chemical TFC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Tianjin Finder Chemical TFC is not a conventional vendor footprint. Its buyer-facing identity centers on Alice TFC/Alice White, a GLP1 Forum sponsor persona, consumer Gmail, UK WhatsApp number, and messaging handles. Registry searches did not tie the English name to a straightforward UK or Chinese corporate record, and the vendor’s own no website position collides with a newly registered finderchem.com domain with recycled certificate history.

Across 87 Finnrick lab tests, 68 passed and 18 failed, for an overall pass rate of 78%. The catalog is uneven rather than uniformly weak. Retatrutide is the clearest strength, while BPC-157 and Tesamorelin are fail-heavy enough to be poor directional choices; Tirzepatide sits in the middle and needs batch-level scrutiny. Ratings contract under stricter methodology, and a Retatrutide endotoxin signal complicates even the stronger GLP-1 story.

A separate high-severity risk is brand confusion. The live tfcpeptides.com impersonation site uses fake contact details and borrowed-looking corporate credentials; forum and Reddit reports describe victims and lookalike Discord/payment approaches. TFC’s official-contact notice helps, but buyers still have to authenticate every channel, payment instruction, and COA rather than trusting a domain or profile picture.

Operationally, TFC shows active forum commerce and a newly announced US warehouse, but spring 2026 reports include long delays, dead or unmatchable tracking, forgotten orders, and weak dispute handling. The report’s conclusion is selective, not blanket: some products merit consideration only with current batch testing, while others point buyers elsewhere.

Inside the full report:

  • Appendix A Finnrick laboratory data with per-product pass/fail rates and methodology-divergence charts for all 5 products
  • Official contact matrix comparing Alice TFC channels against tfcpeptides.com scam indicators
  • RDAP and certificate-transparency analysis of finderchem.com, including recycled-domain history
  • Corporate registry absence trail across UK Companies House and Chinese English-name searches
  • Scam-site exhibits, Reddit/forum victim reports, and lookalike Discord payment patterns
  • Fulfillment timeline covering delay reports, tracking issues, and the US warehouse announcement

Risk assessment

  • Product-specific quality-control risk — high: High for BPC-157 at 42.94% and Tesamorelin at 44.37%, with Tirzepatide weaker at 77.92%; Retatrutide at 91.52% and GHK-Cu at 90.98% are the comparatively stronger TFC choices.
  • Sterility / endotoxin contamination risk — high: Field materials cite endotoxin detection in Retatrutide batch R60022026TFC and community sterility-fail reports involving TFC T30, T40, T60, and R30.
  • Copycat and brand-confusion risk — high: tfcpeptides.com is an active impersonation site with reported victims, false credential claims, and contact details outside Alice TFC’s official channel list.
  • Fulfillment and customer-service reliability risk — medium: Spring 2026 forum reports describe 45-day waits, forgotten orders, dead or unmatchable tracking, and poor dispute handling; some disruption may be customs or capacity related.
  • Corporate-accountability risk — medium: No UK registry match was found and no direct Chinese English-name registry match was verified; the buyer-facing operation relies on a forum persona, Gmail, messaging handles, and an unexplained UK WhatsApp number.